Larvol Delta - A-Study-of-MSDC0602K-to-Assess-Glycemic-Control-and-Cardiovascular-Outcomes-in-Patients-With-PreT2D-or-T2D-and-NAFLDNASH

azemiglitazone (MSDC-0602K) - Cirius Therap

http://clinicaltrials.gov/ct2/show/NCT03970031

Jan 15, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next